Immunosuppressants – TNF alpha inhibitors II

Summary

This tender concerns supplies of infliximab intravenous infusion and adalimumab subcutaneous prefilled pen – parenteral TNF-alpha inhibitors for the treatment of patients in approved indications according to the SmPC as of the bid submission date.